Determination of in Vivo Ultrafiltration Coefficient (KUF) in Patients With Chronic Kidney Disease (CKD)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Patients will be treated with 3 different sizes of xevonta (2 weeks each size) for determination of in vivo KUF following "FDA Guidance for the Content of Premarket Notifications for Conventional and High Permeability Hemodialyzers". In addition blood samples will be collected for determination of removal rates of different small molecules and protein.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Written informed consent obtained from patient or parents/ guardian.
Subject age >= 18
Effective blood flow 350 ml/min and dialysate flow of 500 ml/min
On hemodialysis for a minimum of 3 months
Use of Cimino- or Gore-tex shunts
Routine dialysis-treatment for 240 min
Documented dialysis adequacy parameter that has been stable for past 3 months
Plan to dialyze at participating hemodialysis centre for at least 3-months duration.
Free from any currently known unusual clotting or access problems
Hepatitis B surface antigen (HbsAg) negative, documented within the past 90 days or Hepatitis B surface antibody (anti-HBs) positive.
Anti Hepatitis C Virus (Anti-HCV) negative, documented within the past 90 days
Anti Human Immunodeficiency Virus (Anti HIV) negative, documented within the past 90 days
Hematocrit (HCT) between 25 and 40% or haemoglobin (Hb) not less than 8 g/dL, as documented 14 days prior to the first treatment
Patients who are unable to tolerate an effective blood flow of 350 ml/min
Patients using catheter for dialysis
Pregnant or nursing woman. Women of childbearing potential must agree to avoid pregnancy during the study period by use of hormonal contraception (implantable; patch; oral) and/ or double-barrier methods (any double combination of: IUD; condom with spermicidal gel; diaphragm; sponge; cervical cap)
Previous plan for extended absences from the participating hemodialysis centre
Expected to be transplanted (living related donor) within the maximum of 3 months for the study period
Any serious medical conditions or disability, which in the opinion of the investigator, would interfere with treatment or assessment or preclude completion of the study